Muscular individuals were more likely to be diagnosed with MHS than non-muscular individuals (OR, 1.94; 95% CI, 1.51 to 2.49; P \ 0.001). Males were more likely to be tested after having a possible MH episode (OR, 2.33; 95% CI, 1.45 to 2.1; P\0.001). Logistic regression showed that male sex (OR, 2.28; 95% CI, 1.93 to 2.7; P \ 0.001) and muscular body build (OR, 2.17; 95% CI, 1.21 to 3.9; P = 0.01) were independently predictive of MHS. The interaction between muscular body build and male sex was not significant (P = 0.13). Indications for testing, MH episode vs family history of MH, did not differ between muscular and non-muscular individuals (P = 0.44). Eight of 839 AMRAs and two reports of CHCT had comments describing athletic abilities. Ryanodine receptor type 1 (RYR1) gene mutations were found in five of these athletes. Conclusion Muscular body build and male sex are strongly associated with MHS.
Résumé
Objectif La susceptibilité à l'hyperthermie maligne (SHM) est un trouble de la régulation du calcium dans les muscles squelettiques. Il a été démontré que les personnes musclées couraient un risque 13,6 fois plus élevé de décès pendant des épisodes d'hyperthermie maligne (HM) ainsi qu'un risque plus élevé de récurrence après un premier traitement de la maladie. Vingt-cinq pour cent des épisodes graves d'HM sont survenus chez des athlètes de pointe. Cette étude a examiné l'association entre la SHM et la constitution musculaire. [3] [4] [5] excessive calcium in the muscle cell increases metabolism to the point of producing lethal temperatures. Mutations in the ryanodine receptor type 1 (RYR1) 6 gene are the most frequent genetic changes found in individuals with malignant hyperthermia susceptibility (MHS). Mutations in the alpha one subunit of the voltage-gated calcium channel (the dihydropyridine receptor) 7 are less common than RYR1 mutations. 6, 8 The STAC 3 protein has also been found to be associated with MHS in some myopathic patients. 9 There are 35 mutations in the RYR1 gene and two in the CACNA1S gene, encoding the alpha one subunit of the dihydropyridine receptor, that have been shown to be MH causative. 10 Even with an emerging genetic understanding of MHS, the gold standard for a diagnosis of MH risk in North America remains the caffeine-halothane contracture test (CHCT), which is reported to be 97% sensitive and 78% specific. 11 Muscular individuals have been shown to have a 13.6-fold increased risk of death from MH episodes 12 and are more likely to experience recurrence of MH episodes after initial treatment. 13 Twenty-five percent of severe MH episodes have occurred in elite athletes. 12 There have also been other reports of athletes suffering MH episodes both with 14, 15 and without exposure to anesthesia. [16] [17] [18] It was previously noted that three of 25 Danish individuals who experienced MH episodes were elite athletes competing at the international and Olympic levels. 18 Thus, for this study, we looked for more evidence in the North American Malignant Hyperthermia Registry (NAMHR) that muscularity and athleticism were associated with MHS.
Methods
After institutional review board approval, data were obtained from reports existing in the NAMHR from January 1, 1987 to December 31, 2014, including the Report of Muscle Biopsy and Contracture Testing and the Adverse Metabolic or Muscular Reaction to Anesthesia (AMRA) report. The CHCT is completed by physicians in the MH diagnostic testing centres, and the AMRA is completed by the anesthesiologist or other healthcare provider who observed a possible or actual MH event. The CHCT and AMRA contain a check box for body build that includes options for normal, lean, muscular, obese, postpartum, and other. The judgment of body build is subjective on the part of the physician completing the report and not based on objective measurement of fat or muscle. For purposes of analysis, the cases were sorted into categories of muscular and non-muscular, first on the basis of responses to this check box. If comments reported muscular in a text field as well as noting body build other than muscular in the check box, the case was put into the muscular group for analysis. All forms contain a section for comments. Since 2002, forms include a check box for ''regular regimen of physical activity''. The CHCT form contains the question ''What was the reason for MH diagnostic muscle biopsy?'' with options for fulminant MH episode, possible MH episode with associated AMRA, possible MH episode without AMRA, family history, control, and other. For the purposes of analysis, fulminant MH episodes and possible MH episodes as the reason for biopsy are grouped together and referred to as possible MH episode. These are the probands.
Three thousand twenty-four CHCT reports from individuals in the USA or Canada were examined. These CHCTs were performed after 1979 and before 2013 and include cases in previously published studies from the NAMHR. We excluded 103 of these reports with equivocal results. At the time of testing, the director of the MH diagnostic centre indicated equivocal result to mean that risk of MHS could not be determined. The magnitude of the contractures in the presence of halothane or caffeine were not evaluated in this report. Reports with unknown sex (12) , absent or other body type (335), and 12 reports of CHCT performed prior to standardization 19 were also excluded ( Figure) . Eight hundred thirty-nine AMRAs were reviewed for comments, and CHCT reports were also reviewed for comments regarding athletic achievement and genetic test results.
Analysis was performed using Fisher's exact test for categorical variables. The associations between CHCT result and body build, CHCT result and body build in male and female sex, body build and indication for testing, as well as sex and CHCT result were examined with Fisher's exact test in SPSSÒ (versions 22, 23, & 24; IBM, NY, USA). Since muscularity may be associated with being male, we used logistic regression to determine if muscularity was independently predictive of MHS (over and above sex). We used MHS as the dependent variable and muscularity and sex (as well as their interaction) as the independent variables. There was no correction of P values for multiple comparisons. (Table 1) . Thus, those with muscular body build were more likely than those with non-muscular body build to have CHCT results indicate a diagnosis of MHS (odds ratio [OR], 1.94; 95% confidence interval [CI], 1.5 to 2.5; P \ 0.001). Males were more likely to be diagnosed with MHS by CHCT (OR, 2.33; 95% CI, 1.99 to 2.7) than females (P \ 0.001). Logistic regression showed that muscularity was indeed predictive of MHS independent of sex. The OR for muscularity (adjusted for sex) was 2.17 (95% CI 1.21 to 3.9; P = 0.01), consistent with the unadjusted effect of muscularity on MHS. Being male continued to be predictive of MHS after adjustment for muscularity (OR, 2.28; 95% CI, 1.93 to 2.7; P \ 0.001). There was no significant interaction (P = 0.13) between muscularity and sex, indicating that the effect of muscularity on MHS did not differ appreciably between males and females (or, equivalently, the effect of sex on MHS did not differ appreciably between muscular and nonmuscular individuals) ( Table 2) . With regard to the indication for testing, 458 of 1,091 (42%) males were tested after having a possible MH episode compared with 338 of 1,145 (29.5%) females (P \ 0.001). There was no difference in the indication for testing between those with and without muscular build (P = 0.44). Furthermore, the percentage of muscular probands (those who underwent CHCT because of an episode of suspected MH) was no different from that of muscular individuals who underwent CHCT due to a family history of MH (P = 0.54).
Results

Results of CHCTs
Eight of 839 AMRAs, one of which was linked to a CHCT report, and two other CHCT reports included comments describing athletic abilities (Table 3) . Four of these individuals had known MH causative mutations in RYR1. Two had variants of unproven significance in RYR1, one of whom also had an RYR1 mutation known to be causative of MH.
Discussion
In this report, the CHCT outcome diagnostic of MHS was more strongly related to sex than to report of muscular body build. Our observation that the odds of MHS is more than twice as great in males than in females seems Exercise-induced rhabdomyolysis and weakness.
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Reports with evidence of athleticism and sex; most include body type and some include type 1 ryanodine receptor mutation findings. contradictory to the understanding of MHS as an autosomal dominant condition. Nevertheless, observation of more males than females with a positive CHCT was first reported in 2007 in 1,407 patients evaluated in Sweden. 20 More recently, a consistent parent-of-origin effect was reported for the transmission of MHS in view of the fact that fathers had more affected sons than daughters. 21 Malignant hyperthermia episodes have been reported more often in males than in females in several different types of studies. [22] [23] [24] One might speculate that males experience MH more often than females because of environmental factors. In this report, more males than females presented for a CHCT due to personal experience of an MH event. Nevertheless, in this cohort, there were similar numbers of males and females who underwent CHCT. Sex discrepancy in MH warrants further study.
In the CHCT data in this study, muscular body build was reported in a minority of individuals diagnosed as MHS by CHCT; however, there was a significant association between muscular body build and MHS diagnosed by CHCT. This observation has not been made previously. Logistic regression analysis showed that muscular body build is predictive of MHS independent of sex. There may be ascertainment bias, as a muscular build may be more easily recognized in females than in males. Perhaps many males are subjectively judged to be muscular. Assessment of a larger population with a more objective quantitative measurement of muscularity might yield a different result, as our data may be biased by the subjective nature of the reporting of body build.
The AMRA data, supplemented by a few CHCT reports, show that, although MHS individuals may have mutations in genes encoding proteins involved in the excitationcontraction coupling mechanism in skeletal muscle, some of these individuals perform athletically at high levels. The possibility that an MHS person can be a skilled athlete widens the phenotypic variability of RYR1 mutations. Myopathies related to the RYR1 gene, such as KingDenborough syndrome and central core disease, are not the only clinical presentations of MHS in daily life.
The nature of the data acquisition in this study may produce significant bias. Selection bias is present as all reports were submitted voluntarily, and it may be that only the most severe or memorable cases were reported. Specific questions to elicit reporting of athletic accomplishment were recently added (2015) to reports. Testing for mutations in RYR1 in MHS individuals was experimental until 2005. Also, CHCT is expensive and inconvenient to perform. Patients must travel to only a few available testing centres for muscle biopsy and contracture testing. As a result, our data underrepresent those of lower socioeconomic status. It must be emphasized that all CHCT investigations are done on individuals with an indication, which makes it difficult to apply our results to patients without such medical history.
Conclusion
We report a strong association between muscularity and MHS. Males were more likely to be diagnosed with MHS by muscle contracture testing. Optimistically, as the biology of MH continues to be investigated, the causes of these findings will be elucidated.
